Alto Neuroscience Sees Funding Lasting to 2030 as Depression Drug Heads Toward 2027 Readout
With $319.8m in cash, the neuropsychiatry biotech says it can finance its treatment-resistant depression plans for four more years, while Phase 3 design awaits FDA agreement.
Alto Neuroscience says it has enough money to run until 2030, a notable cushion for a clinical-stage company whose lead asset has yet to produce mid-stage efficacy data. The company reported $319.8m in cash alongside its third-quarter 2026 results on 10 November.
A $100m registered direct offering completed in July contributed to that balance, according to the company. Alto's stated view is that the cash covers its planned development steps without further financing. That is the company's own projection, and the facts available give no breakdown of spending assumptions.
The asset at the centre is ALTO-207, being studied in treatment-resistant depression (TRD). Alto says enrolment in the Phase 2b PACE-1 trial is on track, with topline data expected in the second half of 2027. Before that, the company expects Phase 1 data on a modified-release formulation of the drug by early 2027.
Beyond PACE-1, Alto has sketched two Phase 3 trials: PACE-2, testing ALTO-207 as an add-on therapy, and PACE-3, testing it on its own as monotherapy. Both depend on alignment with the US Food and Drug Administration. The information available does not describe the status of those discussions or give a timetable, so the design of the late-stage programme could still change.
Why it matters
- A cash runway to 2030 means Alto's financing risk is, on its own account, deferred until after the PACE-1 readout and into the planned Phase 3 stage.
- The first data points to watch are the modified-release Phase 1 results in early 2027 and PACE-1 topline in the second half of 2027.
- Phase 3 plans for adjunctive and monotherapy use remain contingent on FDA alignment, so competitors and partners should treat the design as provisional.
Company's press release (SEC filing): Alto Neuroscience, Inc. ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
IRulya Therapeutics reports $105.2M cash as LAM-001 Phase 2 readouts approach
Cerenome reports first CNSide revenue and completes enrolment in Phase 2 glioblastoma trial
BeyondSpring wins FDA Fast Track for plinabulin plus docetaxel in post-immunotherapy NSCLC
Valneva: 94% of adults still seroresponders five years after single IXCHIQ dose
GH Research posts $46.6M nine-month loss as GH001 depression programme nears pivotal stage
